| Advanced and Metastatic Breast Cancer |
1 |
1 |
| Biologic Therapy |
0 |
1 |
| Head and Neck Cancer |
0 |
0.92 |
| Brain Metastasis |
0 |
0.67 |
| Breast Cancer |
0 |
0.67 |
| Antineoplastic Drug |
0 |
0.66 |
| Metastasis |
0 |
0.66 |
| HER2-Positive Breast Cancer |
0 |
0.53 |
| Cancer |
0 |
0.47 |
| Breast |
0 |
0.41 |
| Hodgkin Lymphoma |
0 |
0.4 |
| Toxicology |
0 |
0.4 |
| Brain |
0 |
0.38 |
| Targeted Cancer Therapy |
0 |
0.36 |
| Antibody Drug Conjugates |
0 |
0.35 |
| Humanized Monoclonal Antibody |
0 |
0.32 |
| Blood-Brain Barrier |
0 |
0.27 |
| Food and Drug Administration (FDA) |
0 |
0.14 |
| Radiation Therapy |
0 |
0.12 |
| Tumor |
0 |
0.09 |
| Diarrhea |
0 |
0.07 |
| Blood |
0 |
0.06 |
| Child |
0 |
0.06 |
| Medical Oncology |
0 |
0.06 |
| White Blood Cell Count |
0 |
0.06 |
| Acute Leukemia |
0 |
0.05 |
| Acute Lymphoblastic Leukemia |
0 |
0.04 |
| Tyrosine Kinase Inhibitor |
0 |
0.04 |
| Anemia |
0 |
0.03 |
| Central Nervous System |
0 |
0.03 |
| Chemotherapy |
0 |
0.03 |
| Cytology |
0 |
0.03 |
| Epidemiology |
0 |
0.03 |
| Grant |
0 |
0.03 |
| Hand |
0 |
0.03 |
| Hematology |
0 |
0.03 |
| Hypogonadism |
0 |
0.03 |
| Leukemia |
0 |
0.03 |
| Low Testosterone |
0 |
0.03 |
| Multiple Sclerosis |
0 |
0.03 |
| Neutrophils |
0 |
0.03 |
| Pedal |
0 |
0.03 |
| Residual Disease |
0 |
0.03 |
| Texas |
0 |
0.03 |
| Tyrosine Kinase |
0 |
0.03 |